Mostrar el registro sencillo del ítem

dc.contributor.authorTomás Pérez, Sarai
dc.contributor.authorOto, Julia
dc.contributor.authorAGHABABYAN, KRISTINA
dc.contributor.authorHerranz, Raquel
dc.contributor.authorCuadros Lozano, Aitor
dc.contributor.authorGonzález Cantó, Eva
dc.contributor.authorMc Cormack, Bárbara Andrea
dc.contributor.authorArrés, Judith
dc.contributor.authorCastano, Maria
dc.contributor.authorCana, Fernando
dc.contributor.authorMartínez Fernández, Laura
dc.contributor.authorSantonja, Núria
dc.contributor.authorRamírez, Rocío
dc.contributor.authorHerreros Pomares, Alejandro
dc.contributor.authorCañete Mota, Sarai
dc.contributor.authorLlueca, Antoni
dc.contributor.authorMarí-Alexandre, Josep
dc.contributor.authorMedina, Pilar
dc.contributor.authorGilabert-Estellés, Juan
dc.date.accessioned2023-07-19T08:47:27Z
dc.date.available2023-07-19T08:47:27Z
dc.date.issued2023
dc.identifier.citationTomás-Pérez S, Oto J, Aghababyan C, Herranz R, Cuadros-Lozano A, González-Cantó E, Mc Cormack B, Arrés J, Castaño M, Cana F, Martínez-Fernández L, Santonja N, Ramírez R, Herreros-Pomares A, Cañete-Mota S, Llueca A, Marí-Alexandre J, Medina P and Gilabert-Estellés J (2023) Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and management. Front. Immunol. 14:1111344. doi: 10.3389/fimmu.2023.1111344ca_CA
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/10234/203375
dc.description.abstractIntroduction: High-grade serous ovarian cancer (HGSOC) is the second most frequent gynecological malignancy but the most lethal, partially due to the spread of the disease through the peritoneal cavity. Recent evidence has shown that, apart from their role in immune defense through phagocytosis and degranulation, neutrophils are able to participate in cancer progression through the release of neutrophil extracellular traps (NETs) in a process called NETosis. NETs are composed of DNA, histones, calprotectin, myeloperoxidase (MPO) and elastase and the NETosis process has been proposed as a pre-requisite for the establishment of omental metastases in early stages of HGSOC. Nevertheless, its role in advanced stages remains to be elucidated. Therefore, our principal aim is to characterize a NETosis biomarker profile in biofluids from patients with advanced HGSOC and control women. Methods: Specifically, five biomarkers of NETosis (cell-free DNA (cfDNA), nucleosomes, citrullinated histone 3 (citH3), calprotectin and MPO) were quantified in plasma and peritoneal fluid (PF) samples from patients (n=45) and control women (n=40). Results: Our results showed that HGSOC patients presented a higher concentration of cfDNA, citH3 and calprotectin in plasma and of all five NETosis biomarkers in PF than control women. Moreover, these biomarkers showed a strong ability to differentiate the two clinical groups. Interestingly, neoadjuvant treatment (NT) seemed to reduce NETosis biomarkers mainly systemically (plasma) compared to the tumor environment (PF). Discussion: In conclusion, NETosis biomarkers are present in the tumor environment of patients with advanced HGSOC, which might contribute to the progression of the disease. Besides, plasma cfDNA and calprotectin could represent minimally invasive surrogate biomarkers for HGSOC. Finally, NT modifies NETosis biomarkers levels mainly at the systemic level.ca_CA
dc.format.extent13 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherFrontiers Mediaca_CA
dc.relation.isPartOfFrontiers in Immunology 14:1111344ca_CA
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/ca_CA
dc.subjecthigh-grade serous ovarian cancerca_CA
dc.subjectbiomarkersca_CA
dc.subjectNETosisca_CA
dc.subjectcfDNAca_CA
dc.subjectcalprotectinca_CA
dc.subjectperitoneal fluidca_CA
dc.titleIncreased levels of NETosis biomarkers in high-grade serous ovarian cancer patients’ biofluids: Potential role in disease diagnosis and managementca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttps://doi.org/10.3389/fimmu.2023.1111344
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_CA
project.funder.nameInstituto de Salud Carlos III-Fondo Europeo de Desarrollo Regionalca_CA
project.funder.nameGeneralitat Valencianaca_CA
project.funder.nameSociedad de Obstetricia y Ginecología de la Comunidad Valencianaca_CA
project.funder.nameFundación para la Investigación del Hospital General Universitario de Valenciaca_CA
project.funder.nameSociedad Española de Trombosis y Hemostasiaca_CA
oaire.awardNumberPI17/01945ca_CA
oaire.awardNumberPI17/00495ca_CA
oaire.awardNumberPI20/00075ca_CA
oaire.awardNumberPI22/01872ca_CA
oaire.awardNumberGV/2020/200ca_CA
oaire.awardNumberPrize SOGCV 2019ca_CA
oaire.awardNumberPrize FIHGUV 2019ca_CA
oaire.awardNumberPrize FIHGUV 2020ca_CA
oaire.awardNumberPrize FIHGUV 2021ca_CA
oaire.awardNumberACIF/2020/216ca_CA
oaire.awardNumberFI21/00171ca_CA
dc.subject.ods3. Salud y bienestar


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

http://creativecommons.org/licenses/by/4.0/
Excepto si se señala otra cosa, la licencia del ítem se describe como: http://creativecommons.org/licenses/by/4.0/